Literature DB >> 26885006

Puerarin accelerate scardiac angiogenesis and improves cardiac function of myocardial infarction by upregulating VEGFA, Ang-1 and Ang-2 in rats.

Fen Ai1, Manhua Chen2, Bo Yu1, Yang Yang1, Guizhong Xu1, Feng Gui1, Zhenxing Liu1, Xiangyan Bai1, Zhen Chen1.   

Abstract

OBJECTIVE: The traditional Chinese medicinal puerarin, has long been used to treat cardiovascular diseases, however, the mechanism underlying its effects remain unclear. Here, this study would to investigate the role of puerarin on cardiac angiogenesis and myocardial function induced by myocardial infarction.
METHODS: Puerarin was treated in rats after left anterior descending coronary artery (LAD) ligation and maintained for 4 weeks (diets containing about 50 mg/kg/day or 100 mg/kg/day). After treatment, cardiac function was evaluated by echocardiography and markers of heart failure. Paraffin sections of the heart tissues were used for isolect in GS-IB4 staining. The Mrna and protein expression levels of VEGFA, Ang-1 and Ang-2 were detected by real-time polymerase chain reaction and western blot.
RESULTS: Significantly damaged angiogenesis and slightly increase of VEGFA, Ang-1 and Ang-2 were showed after LAD ligation. Impaired angiogenesis and cardiac function were remarkably improved in puerarin treatment rats with great increase of VEGFA, Ang-1 and Ang-2.
CONCLUSION: The above results demonstrated that puerarin could accelerate cardiac angiogenesis and improve cardiac function of myocardial infarction rats by upregulating VEGFA, Ang-1 and Ang-2.

Entities:  

Keywords:  Puerarin; VEGFA; angiopoietin; cardiac angiogenesis; cardiac function

Year:  2015        PMID: 26885006      PMCID: PMC4723851     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  25 in total

1.  Randomized trial of percutaneous coronary intervention for subacute infarct-related coronary artery occlusion to achieve long-term patency and improve ventricular function: the Total Occlusion Study of Canada (TOSCA)-2 trial.

Authors:  Vladimír Dzavík; Christopher E Buller; Gervasio A Lamas; James M Rankin; G B John Mancini; Warren J Cantor; Ronald J Carere; John R Ross; Deborah Atchison; Sandra Forman; Boban Thomas; Pawel Buszman; Carlos Vozzi; Anthony Glanz; Eric A Cohen; Peter Meciar; Gerald Devlin; Alice Mascette; George Sopko; Genell L Knatterud; Judith S Hochman
Journal:  Circulation       Date:  2006-11-14       Impact factor: 29.690

Review 2.  [Ischemic heart disease, heart failure, and their effects on cognitive function].

Authors:  Michiaki Nagai; Kazuomi Kario
Journal:  Nihon Rinsho       Date:  2014-04

3.  Effect of puerarin on expression of Fas/FasL mRNA in pulmonary injury induced by ischemia-reperfusion in rabbits.

Authors:  Mengxiao Zheng; Dong Song; Ziyin Luo; Zhongqiu Lu; Yiming Wu; Wantie Wang
Journal:  Nat Prod Commun       Date:  2015-02       Impact factor: 0.986

4.  Relation of left atrial dysfunction to ischemic stroke in patients with coronary heart disease (from the heart and soul study).

Authors:  Jonathan M Wong; Christine C Welles; Farnaz Azarbal; Mary A Whooley; Nelson B Schiller; Mintu P Turakhia
Journal:  Am J Cardiol       Date:  2014-03-03       Impact factor: 2.778

Review 5.  Myocardial viability in coronary artery chronic total occlusion.

Authors:  Huseng Vefali; Yugandhar Manda; Jamshid Shirani
Journal:  Curr Cardiol Rep       Date:  2015-01       Impact factor: 2.931

6.  Ability of mechanical reperfusion to salvage myocardium in patients with acute myocardial infarction presenting beyond 12 hours after onset of symptoms.

Authors:  Guido Parodi; Gjin Ndrepepa; Adnan Kastrati; Alberto Conti; Julinda Mehilli; Roberto Sciagrà; Markus Schwaiger; David Antoniucci; Albert Schømig
Journal:  Am Heart J       Date:  2006-12       Impact factor: 4.749

7.  Pharmacokinetic comparisons of puerarin, daidzin and the glucuronide metabolite of puerarin after administration of total flavonoid from Gegen alone and total flavonoid from Gegen combined with total saponin from Sanqi in rats under different physiological states.

Authors:  Xiaoming Liu; Yunli Zhao; Enze Gao; Xing Zhao; Zheng Liu; Zhiguo Yu
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2013-05-28       Impact factor: 3.205

8.  VEGF-C, VEGF-A and related angiogenesis factors as biomarkers of allograft vasculopathy in cardiac transplant recipients.

Authors:  Kevin P Daly; Michael E Seifert; Anil Chandraker; David Zurakowski; Anju Nohria; Michael M Givertz; S Ananth Karumanchi; David M Briscoe
Journal:  J Heart Lung Transplant       Date:  2013-01       Impact factor: 10.247

9.  Angiographic and clinical outcomes of drug-eluting versus bare metal stent deployment in the Occluded Artery Trial.

Authors:  Vladimír Dzavík; Christopher E Buller; Gerard Devlin; Ronald G Carere; G B John Mancini; Warren J Cantor; Pawel E Buszman; James M Rankin; Carlos Vozzi; John R Ross; Sandra Forman; Bruce A Barton; A Gervasio A Lamas; Judith S Hochman
Journal:  Catheter Cardiovasc Interv       Date:  2009-05-01       Impact factor: 2.692

10.  Puerarin attenuates cerebral damage by improving cerebral microcirculation in spontaneously hypertensive rats.

Authors:  Xu-Dong Wu; Chen Wang; Zhen-Ying Zhang; Yan Fu; Feng-Ying Liu; Xiu-Hua Liu
Journal:  Evid Based Complement Alternat Med       Date:  2014-02-13       Impact factor: 2.629

View more
  8 in total

Review 1.  Natural Herbal Medicine as a Treatment Strategy for Myocardial Infarction through the Regulation of Angiogenesis.

Authors:  Mu-Xin Zhang; Yu Song; Wan-Li Xu; Ling-Xiao Zhang; Chao Li; Yun-Lun Li
Journal:  Evid Based Complement Alternat Med       Date:  2022-05-12       Impact factor: 2.650

2.  The Effects of Puerarin on Rat Ventricular Myocytes and the Potential Mechanism.

Authors:  Hao Xu; Manxi Zhao; Shenghui Liang; Quanshu Huang; Yunchuan Xiao; Liang Ye; Qinyi Wang; Longmei He; Lanxiang Ma; Hua Zhang; Li Zhang; Hui Jiang; Xiao Ke; Yuchun Gu
Journal:  Sci Rep       Date:  2016-10-20       Impact factor: 4.379

Review 3.  Anti-Angiogenic Alternative and Complementary Medicines for the Treatment of Endometriosis: A Review of Potential Molecular Mechanisms.

Authors:  Weilin Zheng; Lixing Cao; Zheng Xu; Yuanyuan Ma; Xuefang Liang
Journal:  Evid Based Complement Alternat Med       Date:  2018-10-01       Impact factor: 2.629

4.  Risk gene identification and support vector machine learning to construct an early diagnosis model of myocardial infarction.

Authors:  Hong-Zhi Fang; Dan-Li Hu; Qin Li; Su Tu
Journal:  Mol Med Rep       Date:  2020-06-17       Impact factor: 2.952

5.  New use for old drug: Local delivery of puerarin facilitates critical-size defect repair in rats by promoting angiogenesis and osteogenesis.

Authors:  Huijuan Cao; Lingli Li; Ling Li; Xiangbo Meng; Yanzhi Liu; Wenxiang Cheng; Peng Zhang; Yongbo Gao; Ling Qin; Xinluan Wang
Journal:  J Orthop Translat       Date:  2022-07-31       Impact factor: 4.889

Review 6.  Molecular mechanisms of isoflavone puerarin against cardiovascular diseases: What we know and where we go.

Authors:  Weida Qin; Jianghong Guo; Wenfeng Gou; Shaohua Wu; Na Guo; Yuping Zhao; Wenbin Hou
Journal:  Chin Herb Med       Date:  2022-03-23

Review 7.  Puerarin: A protective drug against ischemia-reperfusion injury.

Authors:  Minglang Gao; Ziyao Zhang; Kai Lai; Yu Deng; Chuanbing Zhao; Zilong Lu; Qing Geng
Journal:  Front Pharmacol       Date:  2022-08-24       Impact factor: 5.988

8.  Mechanism research of Salvia miltiorrhiza on treating myocardial ischemia reperfusion injury according to network pharmacology combined with molecular docking technique.

Authors:  Zhiyan Jiang
Journal:  Medicine (Baltimore)       Date:  2021-12-03       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.